B. Kleiber

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

M. Grever, J. Wright, M. Shah, 2004, Clinical Cancer Research.

427 POSTER Pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I dose-escalation study

A. Tolcher, C. Takimoto, T. Bekaii-Saab, 2008 .

Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary

T. Bekaii-Saab, M. Villalona-Calero, A. Ruppert, 2015, Cancer Chemotherapy and Pharmacology.

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

C. Verschraegen, G. Otterson, Lai Wei, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

Xiaobai Li, T. Bekaii-Saab, M. Zalupski, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients

G. Phillips, G. Otterson, W. Duan, 2006, Cancer Chemotherapy and Pharmacology.

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

M. Grever, J. Wright, H. Kindler, 2004, Clinical Cancer Research.